Introduction {#S0001}
============

Adrenocortical carcinoma (ACC) is a type of rare and aggressive malignancy with a poor 5-year over survival rate which is below 40%.[@CIT0001] Due to the limited treatment options for patients with locally advanced ACC and high risk of relapse even after major operative resection, identifying new prognostic biomarkers and therapeutic targets to improve the therapies for ACC patients is very important.[@CIT0002]--[@CIT0004] In recent decades, clinical bio-samples have been extensively analyzed by gene microarray or RNA-Seq technologies.[@CIT0005],[@CIT0006] Although numerous public transcriptomic datasets with clinical information are available, it is very difficult for researchers or clinicians without bioinformatics training to quickly assess the prognostic value of putative biomarkers. Because getting, processing, filtering, and building survival model of large gene expression datasets are time-consuming and need professional programming skills. In addition, the reported prognostic biomarkers such as *GLUT1*[@CIT0007] and *PTTG1*[@CIT0008] in ACC need to be independently validated in multi-cohorts of different populations before being translated into clinical use.

To build a user-friendly tool that contains ACC gene expression profiles with clinical follow-up data to perform online ACC prognosis analysis, we collected the transcriptomic profiles and clinical information of 259 ACC patients from seven independent cohorts derived from TCGA and GEO to establish OSacc. OSacc is a web-based portal providing survival analysis and risk assessment in ACC datasets using gene symbol as input. This tool offers biomedical researchers and clinicians lacking bioinformatics training to quickly identify putative prognostic biomarkers from gene expression data in ACC. This web tool is available through [<http://bioinfo.henu.edu.cn/ACC/ACCList.jsp>]{.ul}.

Materials And Methods {#S0002}
=====================

Data Collection {#S0002-S2001}
---------------

Messenger RNA (mRNA) expression profiling data with patients' survival information were collected from GEO and TCGA. To gather the data from GEO, the searching keywords "Adrenocortical carcinoma" or "ACC" and "survival" were used in GEO database. The obtained TCGA data are Level 3 RNAseq data with clinical information of ACC patients. The detailed information of above data from GEO and TCGA are described in [Table 1](#T0001){ref-type="table"}. Only dataset with ≥20 ACC samples was included in this study.Table 1Clinical Characteristics Of The ACC Patients Used In OSaccIDPlatformSample TypeNumber Of SamplesDeath EventsMedian OverAll Survival (Months)Ages (Years)Gender (M/F)Stage (I/II/III/IV)ReferenceGSE10927GPL570Primary tumor241719.02 (8.85--32.83)7/17 (25.9%/74.1%)2/11/3/8 (8.3%/45.8%/12.5%/33.3%)7/17 (25.9%/74.1%)[@CIT0020]GSE19750GPL570Primary tumor221836.00 (19.35--103.75)11/11 (50%/50%)1/7/1/4 (7.7%/53.8/7.7%/30.8%)11/11 (50%/50%)[@CIT0008]GSE33371GPL570Primary tumor231615.48 (8.4--61.88)7/16 (30.4%/69.6%)2/10/3/8 (8.7%/43.5%/13%/34.8%)7/16 (30.4%/69.6%)[@CIT0021]GSE49280GPL8490Primary tumor441851.85 (20.70--112.4)8/36 (18.2%/81.8%)--8/36 (18.2%/81.8%)[@CIT0022]GSE76019GPL13158Primary tumor3412^\#^26.25 (17.59--52.59)--10/7/10/7 (29.4%/20.6%/29.4%/20.65)--[@CIT0023]GSE76021GPL96Primary tumor2011\*21.45 (9.21--99.26)--5/5/8/2 (25%/25%/40%/10%)--[@CIT0023]TCGARNAseqPrimary tumor923131.20 (16.80--58.59)60/32 (65.2%/34.8%)9/44/19/18 (10%/48.9%/21.1%/20%)60/32 (65.2%/34.8%)[@CIT0024]Total25912393/112 (45.4%/54.6%)29/84/44/47 (14.3%/41.4%/21.7%/23.2%)93/112 (45.4%/54.6%)[^1][^2]

OSacc Web Tool {#S0002-S2002}
--------------

OSacc is developed as previously described with minor modifications.[@CIT0009]--[@CIT0013] In brief, OSacc contains two main components: storage and data analysis. A Java implementation was used to construct OSacc. OSacc used SQL Server database to provide the storage and management of the gene expression profiles and clinical follow-up data for ACC, and applied the Browser/Server architecture network management system to manage database. R package "survival" was used to perform Cox regression analysis to calculate the hazard ratio, 95% confidence intervals and p-value. R packages "survminer" and "ggplot2" were applied to plot the Kaplan--Meier curves ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf)]{.ul}). The web-based ﻿interface is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1The web interface of OSacc.

Searching Previous Known Prognostic Biomarkers In ACC {#S0002-S2003}
-----------------------------------------------------

All known ACC prognostic biomarkers are searched in PubMed using the combined keywords "ACC" or "Adrenocortical carcinoma", "prognostic" and "biomarkers". Seven prognostic biomarkers were selected from 165 publications. The prognostic values of these previously reported prognostic biomarkers were determined in the combined datasets of ACC patients in OSacc.

Statistical Analysis {#S0002-S2004}
--------------------

GraphPad Prism 8.0 (GraphPad Inc., La Jolla, CA, USA) software was used for statistical analysis. The mRNA expression of *CENPF* in ACC cancer tissues was compared with that in normal tissues, using a Wilcoxon rank-sum test (also called Mann--Whitney test) to calculate a *p* value. A value of *p*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Clinical Characteristics Of ACC Datasets Used In OSacc {#S0003-S2001}
------------------------------------------------------

To obtain the microarray or RNAseq data of ACC with clinical survival information, we searched the GEO and TCGA database. Finally, a total of 259 ACC cases including 167 samples from 6 GEO datasets and 92 samples from TCGA datasets were collected. All of these samples are primary tumors. The median age of these patients is 48 years old and the ratio of male to female is 1:1.2. Two hundred and five patients have OS (overall survival), 34 patients have EFS (event-free survival), and 20 patients have PFS (progression-free survival). A summary of above ACC cohorts is shown in [Table 1](#T0001){ref-type="table"}.

Application Of OSacc Web Tool {#S0003-S2002}
-----------------------------

To measure the correlation between the gene of interest and survival rate, Kaplan--Meier plot was applied in OSacc. To use OSacc, users first input the query gene symbol, choose either one dataset or combined datasets, then select the median or other appropriate cutoff value of gene expression to categorize the ACC patients ([Figure 2A](#F0002){ref-type="fig"}). Combined datasets mean that each cohort was divided separately into strata by selecting the appropriate cutoff value, which are then pooled for survival analysis. Next, users select the specific survival terms including OS, EFS, PFS, DFI (disease-free interval), and PFI (progression-free interval) ([Figure 2B](#F0002){ref-type="fig"}). Users may be also interested in limiting their analysis in a subgroup of patients by selecting the optional confounding clinical factors such as TNM, gender, and race ([Figure 2C](#F0002){ref-type="fig"}--[F](#F0002){ref-type="fig"}). Finally, users click the "Kaplan--Meier plot" button, and the prognostic (Kaplan--Meier, KM) plots with HR, 95% CI and *p* value will be shown on the output web page. *P* value of all genes calculated by Univariate Cox analysis in OSacc are shown in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=215586.xlsx)]{.ul}.Figure 2The screenshot of input parameter in OSacc (**A**--**F**). The options of main input parameters and clinical factors of OSacc.

Validation Of Previously Published ACC Prognostic Biomarkers {#S0003-S2003}
------------------------------------------------------------

To evaluate the performance of OSacc, the prognostic values of 7 ACC prognostic biomarkers were collected from PubMed (shown in [Table 2](#T0002){ref-type="table"}), these 7 reported prognostic biomarkers include 4 unfavorable and 3 favorable ones. To test the OSacc functions, OS was selected as survival term and analyzed in the combined datasets. The cutoff value of splitting the patients was set as upper 25% vs lower 75%. The calculated HR (hazard ratio) and *p* value of these prognostic biomarkers are shown in [Table 2](#T0002){ref-type="table"}. The analysis results in OSacc showed that the prognostic performances of 5 genes (i.e. *GLUT1, PTTG1, MCT2, RARRES2* and *Mki67*) are in accordance with previous reports, while prognostic values of two genes (i.e. *MCT1* and *IGFBP2*) are not the same as previously reported.Table 2Validation Of The 7 Previous Reported Prognostic Biomarkers In OSaccGene SymbolLiterature DataOSacc DataNSurvivalPrognostic ValueMethodReferenceHR (95% CI)*p*-ValueValidation ResultsGLUT1130OSUnfavorableIHC[@CIT0007]7.158 (3.135--16.342)\<0.0001√PTTG122OSUnfavorableWestern blot[@CIT0008]2.391 (1.562--3.661)\<0.0001√MCT278OSFavorableIHC[@CIT0025]0.202 (0.044--0.926)0.0395√MCT178OSFavorableIHC[@CIT0025]1.617 (0.912--2.866)0.1001×RARRES218OSFavorableqPCR[@CIT0026]0.423 (0.243--0.736)0.0023√IGFBP217OSFavorableELISA[@CIT0027]1.700 (1.057--2.734)0.0286×Mki6724OSUnfavorableIHC[@CIT0028]3.051 (1.997--4.661)\<0.0001√Mki6752OSUnfavorableIHC[@CIT0029][^3]

Discovery Of Putative Prognostic Biomarkers In OSacc {#S0003-S2004}
----------------------------------------------------

In addition to validating the reported prognostic markers in independent clinical datasets, OSacc also can be employed to discover novel prognostic markers in ACC. According to the results of univariate Cox analysis in datasets of TCGA, GSE10927, GSE19750 and GSE33371, we selected the genes with *p* value consistently less than 0.05 in multiple datasets for following screening of potential prognostic biomarkers. *CENPF* (Centromere protein F), a key protein associated with the centromere-kinetochore complex, satisfies this criterion. *CENPF* plays a crucial role in chromosomal segregation during mitosis, and its overexpression has been previously reported in several types of solid tumors. Dai et al found that *CENPF* is highly expressed in HCC (Hepatocellular carcinoma) compared to control tissues, and its overexpression is significantly related with serum AFP, advanced differentiation stage and a shorter OS.[@CIT0014] In addition, functional experiments demonstrated that downregulation of *CENPF* inhibits the cell proliferation, formation of colonies and induces tumor growth in nude mice, suggesting its critical role in driving HCC tumorigenesis.[@CIT0014] In 2018, Shahid et al demonstrated that *CENPF* can regulate PC (Prostate cancer) metabolism by modulating pyruvate kinase M2 phosphorylation signaling.[@CIT0015] A recent study showed that downregulation of *CENPF* can change the global metabolic profiles of PC cells and inhibit cell proliferation, indicating that *CENPF* may be a vital regulator of PC metabolism.[@CIT0016] Data-mining of gene expression profile from 4 GEO datasets (GSE10927, GSE12368, GSE90713 and GSE33371) using non-parametric statistical method showed that *CENPF* expression is significantly up-regulated in ACC tissues compared with normal control tissues ([[Figure S2A](https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf)]{.ul}--[[D](https://www.dovepress.com/get_supplementary_file.php?f=215586.pdf)]{.ul}), suggesting that *CENPF* may be linked to pathological process in ACC.

Using OSacc, we firstly found that patients with high expressing *CENPF* had worse OS, while the low expression of *CENPF* group had better OS in TCGA (HR: 10.498, 95% CI: 4.509--24.440, *p*\<0.0001), GSE10927 (HR: 6.990, 95% CI: 2.031--24.060, *p*=0.0020), GSE19750 (HR: 3.738, 95% CI: 1.047--14.349, *p*=0.042), and GSE33371 datasets (HR: 5.075, 95% CI: 1.568--16.420, *p*=0.007) ([Figure 3A](#F0003){ref-type="fig"}--[D](#F0003){ref-type="fig"}). Not surprisingly, in the combined datasets of TCGA, GSE10927, GSE19750 and GSE33371, high *CENPF-*expressing group also showed poor OS (HR: 5.636, 95% CI: 3.414--9.303, *p*\<0.0001) ([Figure 3E](#F0003){ref-type="fig"}), suggesting that *CENPF* is a novel unfavorable prognostic biomarker for OS in ACC. The KM plot cannot be shown in the other three datasets, because GSE49280 does not have the probe for *CENPF*, GSE76019 and GSE76021 do not have OS items.Figure 3Kaplan--Meier plots for high (green) and low (red) *CENPF*-expressing ACC groups in TCGA (**A**), GSE10927 (**B**), GSE19750 (**C**), GSE33371 (**D**) and combined datasets (**E**). Confidence intervals (CI, 95%) and log-rank *p*-values are as shown. The x-axis represents survival time and the y-axis represents survival rate.

Discussion {#S0004}
==========

In this study, we developed a prognosis analysis web tool OSacc that comprises published transcriptomic datasets with clinical information for ACC, and provides survival analysis of ACC patients based on gene expression. The performance of OSacc has been evaluated by seven reported prognostic biomarkers, and the test results showed that 71% (5 of 7) of these reported prognostic biomarkers were confirmed to be prognostic significant in OSacc. The reasons for the insignificance of the 2 genes in OSacc may be due to the use of different detection level/method (ELISA in literature) and data from different ethnic groups.

Because of the importance of prognostic biomarker development in cancers, a couple of prognostic web tools have been developed, such as Proggene,[@CIT0017] OncoLnc[@CIT0018] and cBioportral.[@CIT0019] Prognene is good in performing an extensive survey of prognosis in general cancer types, however it has limited cases of ACCs. OncoLnc was developed to assess the prognostic significance of non-coding genes but not the coding gene. More importantly, *OSacc* has integrated seven ACC cohorts and incorporated the clinical covariates including TNM, gender and race to provide more informative survival plots to the researchers. The different features between OSacc and cBioportal are: (1) OSacc can help users to limit the analysis in a subgroup of patients by selecting the factors including age, gender and TNM, but cBioportal cannot do this; (2) OSacc can analyze the prognostic significance of interesting gene using different cutoffs including median, quartile and trichotomy of the expression level, while cBioportal just has median cutoff; (3) cBioportal just used the single dataset TCGA-ACC for genes' survival analysis while OSacc integrated TCGA and GEO datasets for prognosis analysis. However, there are limitations for OSacc. For example, although combing seven datasets into one pooled analysis can enlarge the number of ACC patients, the quite large differences in overall survival across the studies or heterogeneity in tissue source or different analysis platform might be questioned in the interpretation of prognosis analysis results.

To our knowledge, OSacc is the largest ACC dataset for ACC prognosis analysis. Although the current sample size is only 268 ACC samples available, we will keep adding more ACC data into OSacc database and update the functionality when new ACC expression profiling dataset is available.

Conclusion {#S0005}
==========

OSacc is a free, publicly accessible web tool allowing biomedical researchers and clinicians lacking bioinformatics training to easily analyze the prognostic potency of the genes of interest in ACC.
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[^1]: **Notes:** ^\#^EFS event; \*PFS event.

[^2]: **Abbreviations:** TCGA, TCGA-ACC; NA, not available; M, male; F, female.

[^3]: **Abbreviations:** N, number; OS, overall survival; HR, hazard ratio; CI, confidence intercal; DSS, disease specific survival; DFS, disease free survival; RFS, recurrence free survival; MFS, metastasis free survival; PFS, progression free survival.
